DUL.F Alnylam Pharmaceuticals Inc

Healthcare Biotechnology Frankfurt Exchange
143.25 EUR
Close of Nov 11, 2026
134.70 408.00
Market cap
EUR 19.2B
P/E
8.7x
P/B
5.63x
ROE
93.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is DUL.F undervalued?

Graham number
Price143.25
Graham value97.06
Premium47.6%

DUL.F trades 47.6% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Alnylam Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Alnylam Pharmaceuticals Inc yet.

Alnylam Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops …

Full company profile